Coelho F Fonseca, Guimarães F Loli, Cabral W L Ribeiro, Salles P G Oliveira, Mateo E Cueva, Nogueira e Nogueira L Mendes, Fonseca C E Corradi, Gomes K Braga
Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.
Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.
Genet Mol Res. 2015 Oct 28;14(4):13519-31. doi: 10.4238/2015.October.28.13.
We evaluated the expression of the PCA3 gene in urine from patients with nodular hyperplasia/benign prostatic hyperplasia (PNH) or adenocarcinoma type prostate cancer (PCa).The study included 59 men: 22 with PCa, 26 with PNH, and 11 with no alterations (controls). Patients' urine was collected following prostatic massage and quantified by quantitative real-time PCR for prostate cancer antigen 3 gene (PCA3) and prostate-specific antigen gene (PSA) expression with the ACTB gene for normalization. PCA3 gene expression was detected in 16 patients with PCa and 4 with PNH; in the control group, there was no expression of the gene. No significant difference was observed in the mean levels of PCA3 and PSA expression, the PCA3/PSA ratio, and the total PSA levels when the groups of patients with PCa and PNH were compared. The area under the receiver operating characteristic (ROC) curve was 0.625, 0.596, 0.559, and 0.503 for PCA3 and PSA expression, the PCA3/PSA ratio, and total PSA levels, respectively. The sensitivity and specificity of the PCA3 test were 73 and 85%, respectively. Considering the estimated cutoff values (0.2219 and 0.5007 for PCA3 and PCA3/PSA, respectively), we observed a significant difference between the frequency of individuals with values above in the PCa group compared with the PNH group (P < 0.001). We conclude that the qualitative PCA3 test could be applied to initial screening for differentiation between individuals with PCa or PNH and those without prostate changes.
我们评估了结节性增生/良性前列腺增生（PNH）或前列腺腺癌（PCa）患者尿液中PCA3基因的表达。该研究纳入了59名男性：22名患有PCa，26名患有PNH，11名无病变（对照组）。在前列腺按摩后收集患者尿液，并通过定量实时PCR对前列腺癌抗原3基因（PCA3）和前列腺特异性抗原基因（PSA）的表达进行定量，以β-肌动蛋白基因（ACTB）进行标准化。在16名PCa患者和4名PNH患者中检测到PCA3基因表达；在对照组中，未检测到该基因的表达。比较PCa患者组和PNH患者组时，PCA3和PSA表达的平均水平、PCA3/PSA比值以及总PSA水平均未观察到显著差异。对于PCA3和PSA表达、PCA3/PSA比值以及总PSA水平，受试者操作特征（ROC）曲线下面积分别为0.625、0.596、0.559和0.503。PCA3检测的敏感性和特异性分别为73%和85%。考虑到估计的临界值（PCA3和PCA3/PSA分别为0.2219和0.5007），我们观察到PCa组中值高于临界值的个体频率与PNH组相比存在显著差异（P < 0.001）。我们得出结论，定性PCA3检测可用于初步筛查，以区分患有PCa或PNH的个体与无前列腺变化的个体。
